Pipeline
Target Indications
Discovery
Preclinical
Phase 1
Phase 2
-
MSP-306NASH, IPF, Alopecia
Inflammatory diseasesDevelopment (with Samsung Biologics)Tox. Study (2nd Half of 2022)IND Submission (1st Half of 2024) -
MSP-201Oncology
-
MSP-102Anti-aging,
Infectious diseases